Atıf İçin Kopyala
Şenkal N., Meral R., Medetalibeyoğlu A., Konyaoğlu H., Kose M., Tukek T.
Anatolian journal of cardiology, cilt.24, sa.1, ss.21-29, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
24
Sayı:
1
-
Basım Tarihi:
2020
-
Doi Numarası:
10.14744/anatoljcardiol.2020.57431
-
Dergi Adı:
Anatolian journal of cardiology
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.21-29
-
Anahtar Kelimeler:
coronavirus disease 2019, angiotensin-converting enzyme 2, angiotensin II receptor type 1 blockers, angiotensin-converting enzyme inhibitors, ANGIOTENSIN-CONVERTING ENZYME-2, SARS-CORONAVIRUS, FUNCTIONAL RECEPTOR
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Objective: Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Renin-angiotensin-aldosterone-system (RAAS) inhibitors may increase the expression of angiotensin-converting enzyme 2, which is the receptor for SARSCoV-2 Spike protein. The consequences of using angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the COVID-19 pandemic are unknown.